105603-49-4

Basic information

• Product Name: methyl 5-bromo-2,3-dihydroxybenzoate
• Synonyms: methyl 5-bromo-2,3-dihydroxybenzoate;5-BroMo-2,3-dihydroxybenzoic Acid Methyl Ester
• CAS NO: 105603-49-4
• Molecular Formula: C₈H₇BrO₄
• Molecular Weight: 247.04278
• Product Categories: Amines, Aromatics, Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 105603-49-4.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 334.8±37.0 °C(Predicted)
• Appearance: /
• Density: 1.759±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: DMSO (Slightly), Ethyl Acetate (Slightly)
• PKA: 8.02±0.15(Predicted)
• CAS DataBase Reference: methyl 5-bromo-2,3-dihydroxybenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 5-bromo-2,3-dihydroxybenzoate(105603-49-4)
• EPA Substance Registry System: methyl 5-bromo-2,3-dihydroxybenzoate(105603-49-4)

Safety Data

• Hazardous Substances Data: 105603-49-4(Hazardous Substances Data)

Usage

Description

Methyl 5-bromo-2,3-dihydroxybenzoate is an organic compound characterized by its pale yellow solid appearance. It is a derivative of benzoic acid with a methyl group attached to the benzene ring and features a bromine atom at the 5-position, along with two hydroxyl groups at the 2 and 3 positions. methyl 5-bromo-2,3-dihydroxybenzoate is known for its potential applications in various fields due to its unique chemical structure and properties.

Uses

1. Pharmaceutical Industry:
Methyl 5-bromo-2,3-dihydroxybenzoate is used as an intermediate in the synthesis of pharmaceutical compounds, specifically for the preparation of hydroxyalbuterol. Hydroxyalbuterol is a medication used to treat conditions like asthma and chronic obstructive pulmonary disease (COPD). The compound's unique structure allows it to be a key component in the development of these therapeutic agents.
2. Biochemical Research:
In the field of biochemical research, methyl 5-bromo-2,3-dihydroxybenzoate is utilized as a bisubstrate inhibitor. It displays low inhibitory activity towards sn-glycerol-3-phosphate oxidase, an enzyme found in Trypanosoma brucei brucei, which is the causative agent of African sleeping sickness. By inhibiting this enzyme, the compound can potentially contribute to the development of treatments for this disease.
3. Chemical Synthesis:
Methyl 5-bromo-2,3-dihydroxybenzoate can also be used as a starting material or building block in the synthesis of other organic compounds. Its unique functional groups and structural features make it a valuable component in the creation of various chemical products, including those with potential applications in different industries such as agriculture, materials science, and environmental science.

Upstream product

• 67-56-1 methanol 
• 72517-15-8 2,3-dihydroxy-5-bromobenzoic acid 
• 303-38-8 2,3-Dihydroxybenzoic acid 

Downstream Products

• 182676-91-1 methyl 2,3-bis(benzyloxy)-5-bromobenzoate 
• 854472-28-9 methyl 6-bromo-2,2-diphenyl-1,3-benzodioxole-4-carboxylate 
• 854472-29-0 6-bromo-2,2-diphenyl-1,3-benzodioxole-4-carboxylic acid 
• 854472-32-5 6-cyano-2,2-diphenyl-1,3-benzodioxole-4-carboxylic acid 
• 854472-31-4 methyl 6-cyano-2,2-diphenyl-1,3-benzodioxole-4-carboxylate 
• 854472-55-2 2,2-diphenyl-6-(1,3-thiazol-2-yl)-1,3-benzodioxole-4-carboxylic acid 
• 854472-66-5 6-[(dimethylamino)carbonyl]-2,2-diphenyl-1,3-benzodioxole-4-carboxylic acid 
• 854472-60-9 methyl 2,2-diphenyl-6-(pyridin-4-yl)-1,3-benzodioxole-4-carboxylate 
• 854472-54-1 methyl 2,2-diphenyl-6-(1,3-thiazol-2-yl)-1,3-benzodioxole-4-carboxylate 
• 854472-61-0 2,2-diphenyl-6-(pyridin-4-yl)-1,3-benzodioxole-4-carboxylic acid 
• 854472-44-9 methyl 6-(4-fluorophenyl)-2,2-diphenyl-1,3-benzodioxole-4-carboxylate 
• 854472-68-7 methyl 6-[(E)-3-(dimethylamino)-3-oxoprop-1-enyl]-2,2-diphenyl-1,3-benzodioxole-4-carboxylate 
• 854472-45-0 6-(4-fluorophenyl)-2,2-diphenyl-1,3-benzodioxole-4-carboxylic acid 
• 854472-51-8 6-(4-methylphenyl)-2,2-diphenyl-1,3-benzodioxole-4-carboxylic acid 

Relevant articles and documents

POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1

Described are positive allosteric modulators of muscarinic acetylcholine receptor M1 (mAChR M1), pharmaceutical compositions including the compounds, and methods of using the compounds and compositions for treating neurological disorders, psychiatric diso

Molecular recognition at the active site of catechol-O-methyltransferase (COMT): Adenine replacements in bisubstrate inhibitors

L-Dopa, the standard therapeutic for Parkinson's disease, is inactivated by the enzyme catechol-O-methyltransferase (COMT). COMT catalyzes the transfer of an activated methyl group from S-adenosylmethionine (SAM) to its catechol substrates, such as L-dopa, in the presence of magnesium ions. The molecular recognition properties of the SAM-binding site of COMT have been investigated only sparsely. Here, we explore this site by structural alterations of the adenine moiety of bisubstrate inhibitors. The molecular recognition of adenine is of special interest due to the great abundance and importance of this nucleobase in biological systems. Novel bisubstrate inhibitors with adenine replacements were developed by structure-based design and synthesized using a nucleosidation protocol introduced by Vorbrueggen and co-workers. Key interactions of the adenine moiety with COMT were measured with a radiochemical assay. Several bisubstrate inhibitors, most notably the adenine replacements thiopyridine, purine, N-methyladenine, and 6-methylpurine, displayed nanomolar IC50 values (median inhibitory concentration) for COMT down to 6 nM. A series of six cocrystal structures of the bisubstrate inhibitors in ternary complexes with COMT and Mg2+ confirm our predicted binding mode of the adenine replacements. The cocrystal structure of an inhibitor bearing no nucleobase can be regarded as an intermediate along the reaction coordinate of bisubstrate inhibitor binding to COMT. Our studies show that solvation varies with the type of adenine replacement, whereas among the adenine derivatives, the nitrogen atom at position 1 is essential for high affinity, while the exocyclic amino group is most efficiently substituted by a methyl group. Copyright

Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein

Compounds that are dual aP2/k-FABP inhibitors are provided having the formula wherein A, B, X, Y, R1, R2 and R3 are as described herein. A method is also provided for treating diabetes and related diseases, especially Type II diabetes, employing dual aP2/k-FABP inhibitors alone or in combination with at least one other antidiabetic agent such as metformin, glyburide, troglitazone and/or insulin.